A claims-based Markov model for Crohn's disease

被引:20
作者
Malone, D. C. [1 ]
Waters, H. C. [2 ]
Van Den Bos, J. [3 ]
Popp, J. [2 ]
Draaghtel, K. [3 ]
Rahman, M. I. [4 ]
机构
[1] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA
[2] Centocor Ortho Biotech Serv LLC, Horsham, PA 19044 USA
[3] Milliman Inc, Denver, CO 80202 USA
[4] Ortho Clin Diagnost, Raritan, NJ 08869 USA
关键词
COST; INFLIXIMAB; THERAPY; METAANALYSIS; PREVALENCE; MANAGEMENT; RECURRENCE; EMPLOYMENT; RESECTION; CARE;
D O I
10.1111/j.1365-2036.2010.04356.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Crohn's disease is a chronic condition that often presents in early adulthood. Aim To evaluate health care costs and costs per quality-adjusted life year (QALY) for Crohn's disease. Methods A Markov model was developed using administrative claims data for patients aged >= 18 years with >= 3 years of continuous enrolment from 2000 to 2008 and >= 2 Crohn's disease claims. Disease states (remission, mild-moderate, moderate-severe, and severe-fulminant) were defined using the American College of Gastroenterology treatment guidelines criteria. Transition probabilities were calculated from consecutive 6-month periods. Costs were determined from paid claims and QALY utilities were obtained from the literature. The model assumed a 30-year-old patient at the time of entry into the model. Results There were 40 063 patients identified, with a total of 420 773 cycles [remission (197 111; 46.8%), mild-moderate (44 024; 10.5%), moderate-severe (132 695; 31.5%), severe-fulminant (46 925; 11.2%)]. The costs/QALY for remission, mild-moderate, moderate-severe, and severe-fulminant disease states respectively were $2896, $8428, $11 518 and $69 277 for males and $2896, $8426, $22 633 and $69 412 for females. Conclusions Overall, health care costs for patients with Crohn's disease increased with disease severity. Although the probabilities of transitioning from other health states to the severe-fulminant disease state were low, the cost/QALY was high.
引用
收藏
页码:448 / 458
页数:11
相关论文
共 28 条
[1]   Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data [J].
Bodger, K. ;
Kikuchi, T. ;
Hughes, D. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (03) :265-274
[2]   Meta-analysis: mortality in Crohn's disease [J].
Canavan, C. ;
Abrams, K. R. ;
Mayberry, J. F. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (08) :861-870
[3]  
CLARK W, 2003, HLTH TECHNOL ASSES, V7
[4]  
Cohen RD, 2000, AM J GASTROENTEROL, V95, P524
[5]  
Drummond MF, 1987, METHODS EC EVALUATIO, P126
[6]  
DRUMMOND MF, 1987, EC APPRAISAL HLTH TE, P15
[7]   Unemployment and disability in patients with moderately to severely active Crohn's disease [J].
Feagan, BG ;
Bala, M ;
Yan, S ;
Olson, A ;
Hanauer, S .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2005, 39 (05) :390-395
[8]  
Feagan BG, 2000, AM J GASTROENTEROL, V95, P1955
[9]   An evaluation of utility measurement in Crohn's disease [J].
Gregor, JC ;
McDonald, JWD ;
Klar, N ;
Wall, R ;
Atkinson, K ;
Lamba, B ;
Feagan, BG .
INFLAMMATORY BOWEL DISEASES, 1997, 3 (04) :265-276
[10]  
Hanauer SB, 2001, AM J GASTROENTEROL, V96, P635